Lance L. Munn
Harvard University
208 Papers
2.3K Citations
Lance L. Munn is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 70, co-authored 177 publications. Previous affiliations of Lance L. Munn include Rice University & Bucknell University.
Chat about Author
Papers
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Christopher G. Willett,Yves Boucher,Emmanuelle di Tomaso,Dan G. Duda,Lance L. Munn,Ricky T. Tong,Daniel C. Chung,Dushyant V. Sahani,Sanjeeva P. Kalva,Sergey V. Kozin,Mari Mino,Kenneth S. Cohen,David T. Scadden,Alan C. Hartford,Alan J. Fischman,Jeffrey W. Clark,David P. Ryan,Andrew X. Zhu,Lawrence S. Blaszkowsky,Helen X. Chen,Paul C. Shellito,Gregory Y Lauwers,Rakesh K. Jain +22 more
TL;DR: It is shown that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients.
•Journal Article
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Christopher G. Willett,Yves Boucher,Emmanuelle di Tomaso,Dan G. Duda,Lance L. Munn,Ricky T. Tong,Daniel C. Chung,Dushyant V. Sahani,Sanjeeva P. Kalva,Sergey V. Kozin,Mari Mino,Kenneth S. Cohen,David T. Scadden,Alan C. Hartford,Alan J. Fischman,Jeffrey W. Clark,David P. Ryan,Andrew X. Zhu,Lawrence S. Blaszkowsky,Helen X. Chen,Paul C. Shellito,Gregory Y Lauwers,Rakesh K. Jain +22 more
TL;DR: In this article, a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients.
1.7K
Normalization of the vasculature for treatment of cancer and other diseases
TL;DR: The pathophysiology of tumor angiogenesis, the molecular underpinnings and functional consequences of vascular normalization, and the implications for treatment of cancer and nonmalignant diseases are reviewed.
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.
Frank Winkler,Sergey V. Kozin,Ricky T. Tong,Sung-Suk Chae,Michael F. Booth,Igor Garkavtsev,Lei Xu,Daniel J. Hicklin,Dai Fukumura,Emmanuelle di Tomaso,Lance L. Munn,Rakesh K. Jain +11 more
TL;DR: It is shown that VEGFR2 blockade creates a "normalization window"--a period during which combined radiation therapy gives the best outcome, characterized by an increase in tumor oxygenation, which is known to enhance radiation response.
1.3K
Lymphatic metastasis in the absence of functional intratumor lymphatics.
Timothy P. Padera,Ananth Kadambi,Emmanuelle di Tomaso,Carla Mouta Carreira,Edward B. Brown,Yves Boucher,Noah C. Choi,Douglas J. Mathisen,John C. Wain,Eugene J. Mark,Lance L. Munn,Rakesh K. Jain +11 more
TL;DR: Functional lymphatics associated with mouse tumors expressing normal or elevated levels of vascular endothelial growth factor–C (VEGF-C) are examined to suggest that the functional lymphatics in the tumor margin alone are sufficient for lymphatic metastasis and should be targeted therapeutically.
1K